TY - JOUR
T1 - Life-threatening infections in children in Europe (the EUCLIDS Project)
T2 - a prospective cohort study
AU - Martinón-Torres, Federico
AU - Salas, Antonio
AU - Rivero-Calle, Irene
AU - Cebey-López, Miriam
AU - Pardo-Seco, Jacobo
AU - Herberg, Jethro A.
AU - Boeddha, Navin P.
AU - Klobassa, Daniela S.
AU - Secka, Fatou
AU - Paulus, Stephane
AU - de Groot, Ronald
AU - Schlapbach, Luregn J.
AU - Driessen, Gertjan J.
AU - Anderson, Suzanne T.
AU - Emonts, Marieke
AU - Zenz, Werner
AU - Carrol, Enitan D.
AU - van der Flier, Michiel
AU - Levin, Michael
AU - Levin, Michael
AU - Coin, Lachlan
AU - Gormley, Stuart
AU - Hamilton, Shea
AU - Herberg, Jethro
AU - Hourmat, Bernardo
AU - Hoggart, Clive
AU - Kaforou, Myrsini
AU - Sancho-Shimizu, Vanessa
AU - Wright, Victoria
AU - Abdulla, Amina
AU - Agapow, Paul
AU - Bartlett, Maeve
AU - Bellos, Evangelos
AU - Eleftherohorinou, Hariklia
AU - Galassini, Rachel
AU - Inwald, David
AU - Mashbat, Meg
AU - Menikou, Stefanie
AU - Mustafa, Sobia
AU - Nadel, Simon
AU - Rahman, Rahmeen
AU - Thakker, Clare
AU - Bokhandi, Sumit
AU - de Groot, Ronald
AU - van der Flier, Michiel
AU - Sanders, Elisabeth AM
AU - Dekkers, Roel
AU - Heidema, Jojanneke
AU - Miedema, Carien J.
AU - Wolfs, Tom FW
N1 - Funding Information:
This project has received funding from the European Union's Seventh Framework programme under EC-GA number 279185 (EUCLIDS). This study received support from the Instituto de Salud Carlos III (Proyecto de Investigación en Salud, Acción Estratégica en Salud), project GePEM ISCIII/PI16/01478/Cofinanciado FEDER, and project ReSVinext ISCIII/PI16/01569/Cofinanciado FEDER; Consellería de Sanidade, Xunta de Galicia (RHI07/2-intensificación actividad investigadora, PS09749 and 10PXIB918184PR), Instituto de Salud Carlos III (Intensificación de la actividad investigadora 2007–2012, PI16/01569), Fondo de Investigación Sanitaria (FIS; PI070069/PI1000540) del plan nacional de I+D+I and ‘fondos FEDER’, and 2016-PG071 Consolidación e Estructuración REDES 2016GI-1344 G3VIP (Grupo Gallego de Genética Vacunas Infecciones y Pediatría, ED341D R2016/021). This study was funded by grants from the Swiss National Science Foundation (342730_153158/1), the Swiss Society of Intensive Care, the Bangerter Foundation, the Vinetum and Borer Foundation, and the Foundation for the Health of Children and Adolescents. This study was funded by grant Abt.08 -16.K-8/2012–20 of the Department for Science and Research of the Styrian federal government (Austria) and a European Society for Paediatric Infectious Diseases (ESPID) grant 2011 for “Endowed professorship for paediatric infectious diseases paying particular attention to meningococcal disease at the Department of General Pediatrics of the Medical University of Graz”. This research was supported by the UK National Institute for Health Research (NIHR) Newcastle Biomedical Research Centre based at Newcastle Hospitals National Health Service (NHS) Foundation Trust and Newcastle University, UK. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR, or the UK Department of Health.
Publisher Copyright:
© 2018 Elsevier Ltd
PY - 2018/6/1
Y1 - 2018/6/1
N2 - Background: Sepsis and severe focal infections represent a substantial disease burden in children admitted to hospital. We aimed to understand the burden of disease and outcomes in children with life-threatening bacterial infections in Europe. Methods: The European Union Childhood Life-threatening Infectious Disease Study (EUCLIDS) was a prospective, multicentre, cohort study done in six countries in Europe. Patients aged 1 month to 18 years with sepsis (or suspected sepsis) or severe focal infections, admitted to 98 participating hospitals in the UK, Austria, Germany, Lithuania, Spain, and the Netherlands were prospectively recruited between July 1, 2012, and Dec 31, 2015. To assess disease burden and outcomes, we collected demographic and clinical data using a secured web-based platform and obtained microbiological data using locally available clinical diagnostic procedures. Findings: 2844 patients were recruited and included in the analysis. 1512 (53·2%) of 2841 patients were male and median age was 39·1 months (IQR 12·4–93·9). 1229 (43·2%) patients had sepsis and 1615 (56·8%) had severe focal infections. Patients diagnosed with sepsis had a median age of 27·6 months (IQR 9·0–80·2), whereas those diagnosed with severe focal infections had a median age of 46·5 months (15·8–100·4; p<0·0001). Of 2844 patients in the entire cohort, the main clinical syndromes were pneumonia (511 [18·0%] patients), CNS infection (469 [16·5%]), and skin and soft tissue infection (247 [8·7%]). The causal microorganism was identified in 1359 (47·8%) children, with the most prevalent ones being Neisseria meningitidis (in 259 [9·1%] patients), followed by Staphylococcus aureus (in 222 [7·8%]), Streptococcus pneumoniae (in 219 [7·7%]), and group A streptococcus (in 162 [5·7%]). 1070 (37·6%) patients required admission to a paediatric intensive care unit. Of 2469 patients with outcome data, 57 (2·2%) deaths occurred: seven were in patients with severe focal infections and 50 in those with sepsis. Interpretation: Mortality in children admitted to hospital for sepsis or severe focal infections is low in Europe. The disease burden is mainly in children younger than 5 years and is largely due to vaccine-preventable meningococcal and pneumococcal infections. Despite the availability and application of clinical procedures for microbiological diagnosis, the causative organism remained unidentified in approximately 50% of patients. Funding: European Union's Seventh Framework programme.
AB - Background: Sepsis and severe focal infections represent a substantial disease burden in children admitted to hospital. We aimed to understand the burden of disease and outcomes in children with life-threatening bacterial infections in Europe. Methods: The European Union Childhood Life-threatening Infectious Disease Study (EUCLIDS) was a prospective, multicentre, cohort study done in six countries in Europe. Patients aged 1 month to 18 years with sepsis (or suspected sepsis) or severe focal infections, admitted to 98 participating hospitals in the UK, Austria, Germany, Lithuania, Spain, and the Netherlands were prospectively recruited between July 1, 2012, and Dec 31, 2015. To assess disease burden and outcomes, we collected demographic and clinical data using a secured web-based platform and obtained microbiological data using locally available clinical diagnostic procedures. Findings: 2844 patients were recruited and included in the analysis. 1512 (53·2%) of 2841 patients were male and median age was 39·1 months (IQR 12·4–93·9). 1229 (43·2%) patients had sepsis and 1615 (56·8%) had severe focal infections. Patients diagnosed with sepsis had a median age of 27·6 months (IQR 9·0–80·2), whereas those diagnosed with severe focal infections had a median age of 46·5 months (15·8–100·4; p<0·0001). Of 2844 patients in the entire cohort, the main clinical syndromes were pneumonia (511 [18·0%] patients), CNS infection (469 [16·5%]), and skin and soft tissue infection (247 [8·7%]). The causal microorganism was identified in 1359 (47·8%) children, with the most prevalent ones being Neisseria meningitidis (in 259 [9·1%] patients), followed by Staphylococcus aureus (in 222 [7·8%]), Streptococcus pneumoniae (in 219 [7·7%]), and group A streptococcus (in 162 [5·7%]). 1070 (37·6%) patients required admission to a paediatric intensive care unit. Of 2469 patients with outcome data, 57 (2·2%) deaths occurred: seven were in patients with severe focal infections and 50 in those with sepsis. Interpretation: Mortality in children admitted to hospital for sepsis or severe focal infections is low in Europe. The disease burden is mainly in children younger than 5 years and is largely due to vaccine-preventable meningococcal and pneumococcal infections. Despite the availability and application of clinical procedures for microbiological diagnosis, the causative organism remained unidentified in approximately 50% of patients. Funding: European Union's Seventh Framework programme.
UR - http://www.scopus.com/inward/record.url?scp=85046161618&partnerID=8YFLogxK
U2 - 10.1016/S2352-4642(18)30113-5
DO - 10.1016/S2352-4642(18)30113-5
M3 - Article
AN - SCOPUS:85046161618
SN - 2352-4642
VL - 2
SP - 404
EP - 414
JO - The Lancet Child and Adolescent Health
JF - The Lancet Child and Adolescent Health
IS - 6
ER -